Review

纳米尺度的表没食子儿茶素没食子酸酯：一种新的癌症治疗策略

Epigallocatechin-3-gallate at the nanoscale: a new strategy for cancer treatment

PHARMACEUTICAL BIOLOGY

影响因子:4.8

分区:医学3区 / 医学实验技术2区药学2区植物科学2区

发表日期:2024 Dec

作者: Wenxue Sun, Yizhuang Yang, Cuiyun Wang, Mengmeng Liu, Jianhua Wang, Sen Qiao, Pei Jiang, Changgang Sun, Shulong Jiang

DOI: 10.1080/13880209.2024.2406779

摘要

表没食子儿茶素没食子酸酯（EGCG）是绿茶中的主要儿茶素，已显示出通过调控多条信号通路对抗多种类型癌细胞的潜力。然而，其低生物利用度和快速降解限制了其临床应用。本文综述了纳米包封技术在增强EGCG稳定性、生物利用度及治疗效果方面的潜力。我们检索了自2019年至今的PubMed数据库，以“epigallocatechin gallate”、“EGCG”和“nanoparticles”作为关键词，筛选相关文献。本综述考察了近年来在纳米工程技术方面的进展，涉及将EGCG包封于各种纳米载体中的方法，重点评估所用的纳米粒子类型、合成方法及优化药物递送、诊断能力和治疗效果的技术。纳米粒子改善了EGCG的理化稳定性和药代动力学，从而增强了癌症治疗的疗效。纳米包封实现了靶向药物递送、控释、增强细胞摄取及减少EGCG的早期降解。研究显示，载有EGCG的纳米粒子在多种模型中显著抑制肿瘤生长，表现出通过主动靶向机制增强的穿透性和疗效。EGCG的纳米包封在肿瘤学中代表一种有前景的方法，具有多重治疗优势，超越其未包封形态。尽管目前的研究结果令人鼓舞，但仍需进一步研究以优化这些纳米系统的设计，确保其安全性、有效性及临床应用的可行性。

Abstract

Epigallocatechin-3-gallate (EGCG), the predominant catechin in green tea, has shown the potential to combat various types of cancer cells through its ability to modulate multiple signaling pathways. However, its low bioavailability and rapid degradation hinder its clinical application.This review explores the potential of nanoencapsulation to enhance the stability, bioavailability, and therapeutic efficacy of EGCG in cancer treatment.We searched the PubMed database from 2019 to the present, using 'epigallocatechin gallate', 'EGCG', and 'nanoparticles' as search terms to identify pertinent literature. This review examines recent nano-engineering technology advancements that encapsulate EGCG within various nanocarriers. The focus was on evaluating the types of nanoparticles used, their synthesis methods, and the technologies applied to optimize drug delivery, diagnostic capabilities, and therapeutic outcomes.Nanoparticles improve the physicochemical stability and pharmacokinetics of EGCG, leading to enhanced therapeutic outcomes in cancer treatment. Nanoencapsulation allows for targeted drug delivery, controlled release, enhanced cellular uptake, and reduced premature degradation of EGCG. The studies highlighted include those where EGCG-loaded nanoparticles significantly inhibited tumor growth in various models, demonstrating enhanced penetration and efficacy through active targeting mechanisms.Nanoencapsulation of EGCG represents a promising approach in oncology, offering multiple therapeutic benefits over its unencapsulated form. Although the results so far are promising, further research is necessary to fully optimize the design of these nanosystems to ensure their safety, efficacy, and clinical viability.